

## S. JORDAN ASSOCIATES

LIFE SCIENCES CONSULTANT & REGISTERED REPRESENTATIVE

## CAPABILITIES

## For Institutional Investors Use Only

Securities are offered through Finalis Securities LLC Member FINRA/SIPC. S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.

## DISCLOSURE STATEMENT

This presentation, including without limitation any information, estimates or projections contained herein or made in connection with this presentation, either in writing or orally or other format, (this "Presentation") is being furnished by or on behalf of The Translational Genomics Research Institute ("Company"). Any information contained in this Presentation is for informational purposes only and has not been independently verified. The Presentation may contain confidential and/or proprietary information and is provided for the exclusive use of the recipient and may not be reproduced, provided or disclosed to others, or used for any other purpose, without written authorization by S. Jordan Associates and the Company, and upon request must be returned to the Company or S. Jordan Associates.

S. Jordan Associates is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner, and any recipient of this Presentation acknowledges and agrees that S. Jordan Associates is not acting, nor is required to act, in any such capacity in connection with any transaction involving the Company pertaining to the matters contained herein. This Presentation is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any recipient. Recipients are responsible for their own investment research and investment decisions.

Recipients should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on this Presentation constitutes a solicitation, recommendation, endorsement, or offer by the Company or S. Jordan Associates or any of their affiliates or any third party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. This Presentation does not address the circumstances of any particular individual or entity. S. Jordan Associates is not a fiduciary by virtue of any person's use of or access to this Presentation or the information contained herein. Recipients alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other content in this Presentation before making any decisions based on such information or other content.

The Company, S. Jordan and Associates and their respective affiliates make no representation or warranty (express or implied) as to the accuracy or completeness of this Presentation and none of them will have any liability for any recipient's use of this Presentation or any other oral, written, or other communications transmitted to the recipient in the course of its evaluation of the Company, including without limitation, any improper use or defamatory, offensive, or illegal conduct of recipient or any other users. This Presentation is provided on an "as is" basis without warranties of any kind, either express or implied, including but not limited to warranties of title or implied warranties of merchantability or fitness for a particular purpose. The disclaimers of liability contained herein apply to any damages or injury caused by any failure of performance, error, omission, interruption, defect, delay in operation or transmission, computer virus, communication recipients agree not to hold Company or S. Jordan Associates or any of their affiliates or any third-party service provider liable for any possible claim for damages arising from any use by or decision made by recipients based on information or other content made available to recipients in or through this Presentation.

Any recipient of this Presentation acknowledges and agrees that the Company, S. Jordan Associates and their affiliates are not liable for any use of this Presentation or reliance on any information from this Presentation. In no event will the Company, S. Jordan Associates or any of their affiliates be liable for any direct, indirect, incidental, special, or consequential damages (including but not limited to lost profits or trading losses) arising out of the use of or inability to use this Presentation. S. Jordan Associates and their affiliates do not endorse and are not responsible for the accuracy or reliability of any opinion, advice, information or statement on this Presentation.

This Presentation includes certain forward-looking statements, estimates and projections provided by, and with respect to the anticipated future performance of, the Company. In some cases, recipients can identify forward-looking statements by terminology such as "may", "estimates", "anticipates", "intends", "will", "should", "could", "expects", or "predicts". Such statements, estimates, and projections reflect various assumptions and elements of subjective judgment made by management concerning anticipated results, which are subject to business, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the Company and which may or may not prove to be correct. This Presentation contains certain projected financial information that reflects management's projections as to anticipated future results based upon assumptions that are inherently uncertain, including assumptions as to the size of the market in which it competes, general industry conditions, and other factors. The assumptions are based upon management's judgment. As a result, no representation or warranty is made as to the factors.

This Presentation is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. Recipients should not regard this Presentation as a substitute for the exercise of their own judgment. The Company reserves the right to negotiate with one or more prospective third parties at any time and to enter into a definitive agreement relating to a transaction with the Company without prior notice to the recipient or other prospective third parties. Also, the Company reserves the right, at any time, to terminate the further participation in the investigation and process by any party and to modify any procedures without giving advance notice or providing any reason thereof. The Company also reserves the right during the evaluation period to take any action, whether within or outside the ordinary course of business. Neither this Presentation nor its delivery to recipients shall constitute or be construed to be an offer to sell any securities of the Company nor S. Jordan Associates expects to update or otherwise revise this Presentation or other materials supplied herewith.

# OPERATIONAL. BUSINESS DEVELOPMENT, AND BANKING EXPERIENCE



### **SCOTT JORDAN**

Founder / CEO S Jordan Associates (SJA)

- C-Level Operations Experience Chief Financial Officer (CFO) / Chief Business Officer (CBO) for private and public (NASDAQ) biotechnology companies leveraging nondilutive funding, strategic partnerships, and the capital markets to advance development programs through proof-of-concept clinical studies
- Business Development / Investment Banking Expertise Over 30 years of structuring licensing agreements, closing Seed / Series rounds, cross-over financings, equity lines, and \$1 / \$3 shelf offerings
- Facilitated "Exits" via Mergers and Acquisition (M&A), Initial Public Offerings (IPOs), and Alternative Public Offerings (APOs - Special Purpose Acquisition Companies - SPAC / reverse mergers)
- Extensive network of biopharmaceutical, diagnostics, and medical device C-Level executives, sell-side investment bankers, equity analysts, and buy-side investors
- MBA, FINRA Licensed (Series 7, 66, 63, 31) and Level II Candidate in the Chartered Financial Analyst (CFA) Program





## S. JORDAN ASSOCIATES – SERVICE OFFERINGS

#### NON-DILUTIVE FUNDING

S. Jordan Associates (SJA) is proficient identifying non-dilutive capital sources from Local, State (Cancer Prevention Research Institute of Texas - CPRIT) and Federally sponsored institutions (SBIR)

Guide clients through the application process and work collaboratively to implement best practices leading to successful awards

#### PRIVATE COMPANY FINANCINGS

SJA exceeds client financing objectives by accessing the company's extensive network of institutional, angel group syndicates, and alternative investors (accredited, family offices, hedge funds) to finance early to mid-stage biotech companies through major value inflection points / milestones

Effective at negotiating and closing Seed / Series rounds with institutional capital sources (venture capital, cross-over) and identifying / gaining commitment from "Lead" sponsors pivotal to securing investor syndicates



#### STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

SJA engages with strategic partners seeking to outsource R&D via traditional and novel partnerships (option-to-buy / license). Services provided to emerging growth companies includes:

- Assessing the competitive landscape and benchmarking against industry deal averages (upfront payments, royalties, milestones)
- Targeted outreach to large biopharmaceutical, diagnostic, and medical device companies managed within SJA's proprietary Customer Relationship Management (CRM) system
- Negotiating term sheets with prospective partners optimizing client deal metrics and shareholder return on investment (ROI)

#### "EXITS" / PUBLIC COMPANY FINANCINGS

SJA works diligently evaluating viable exit / public company financing vehicles including mergers and acquisitions, initial public offerings (IPOs), and alternative public offerings (reverse merger, SPAC) aligned with capital market conditions and company-specific attributes

Alternative Public Offerings (APOs):

Leverage strong relationships with sell-side banks and SPAC sponsors identifying public shells, submitting proposals to win auctions, and negotiating / closing term sheets on behalf of private companies seeking listings on public market exchanges (e.g. NASDAQ)



#### **NON-DILUTIVE FINANCING – INOMAGEN THERAPEUTICS**

- S. Jordan Associates (SJA) acted as financial advisor to Inomagen Therapeutics assisting with securing a \$3.67 million NIH SBIR Fast Track Phase 1 / 2 Grant to develop gene therapy for Atrial Fibrillation (AF)
- The award includes \$462,689 from the National Heart, Lung, and Blood Institute (NHLBI) to complete the 'Phase 1' segment of development which includes optimizing gene doses and electroporation parameters required for atrial gene delivery
- Upon successful completion of the Phase 1 segment, RTI eligible to receive an additional \$3,212,600 in NIH funding to carry out the 'Phase 2' segment, which will include determining optimal dose of gene therapy required to attenuate established electrical remodeling in AF

#### ABOUT INOMAGEN THERAPEUTICS, https://inomagen.com

• Inomagen Therapeutics, Inc. is a privately held biotechnology company with technology licensed from Northwestern University (NU) dedicated to delivering the promise of gene therapy for treating serious cardiovascular diseases such as atrial fibrillation





Non-Dilutive Fundina



#### **PRIVATE COMPANY FINANCING – IMMUNOGENESIS**

- S. Jordan Associates (SJA) acted as financial advisor to ImmunoGenesis assisting with raising a \$14.5M convertible note
- Lead investors include the founders of Chicago-based hedge funds (Magnetar Capital and Peak6), early-stage venture capitalists (BioAdvance, Texas Halo Fund) and secondary markets trading firm / crossover investor (Adit Ventures)

#### ABOUT IMMUNOGENESIS, https://www.immunogenesis.com/

- ImmunoGenesis formed to develop products from the lab of Dr. Michael A. Curran, Associate Professor, Department of Immunology at MD Anderson Cancer Center who worked closely with Nobel Laureate, Dr. James Allison, and is on the patent for CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 – Ipilimumab / Yervoy) inhibition
- Development programs to overcome immune resistance in "cold" tumors unresponsive to current checkpoint inhibition therapies which comprise the majority of all cancers






# ACHIEVEMENTS 2016 - 2020

#### **NON-DILUTIVE FUNDING**

- Secured awards from the Cancer Prevention Research Institute of Texas (CPRIT) resulting in ~\$35M of non-dilutive capital advancing two drug programs through IND Phase 1 / 2 clinical trials
- Leverage non-dilutive capital during early stages of development to reach critical milestones resulted In subsequent financing rounds priced at higher valuations



### STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

- Out-licensed South Korean rights to Salarius Pharmaceuticals / Iterion
  Therapeutics' lead compounds (Seclidemstat, Tegavivint) to HLB Lifesciences
  Co.
- Negotiated licensing terms including upfront payment, milestones, and royalties
- Established joint research committees monitoring progress and report findings
  to respective board members



### PRIVATE COMPANY FINANCINGS

Raised development funding from academic Institutions, angel groups, and accredited / institutional investors (venture capital)



### "EXITS" / PUBLIC COMPANY FINANCINGS

- Identified, awarded, negotiated, and closed a term sheet / public shell with Flex Pharma (FLRX) resulting in Salarius Pharmaceuticals Listing on NASDAQ via a reverse merger in 2019
- Facilitated a \$10.9M equity line with Aspire Capital, a private, long-only investment fund focused on making investments in publicly traded companies
- Closed a \$11M \$1 offering with Ladenburg Thalmann funding Salarius through Phase 1 / 2 clinical milestones



Similar results are not guaranteed; based on investor demand and general market factors

## TOMBSTONES 2016 - 2020





## TRANSACTION HISTORY 2005 - 2016







IMAGING

Capital raises, licensing agreements, and M&A / public offerings facilitated as a placement agent of S. Jordan Associates and Healthios Capital Markets.

#### ALTERNATIVE PUBLIC OFFERINGS (APO)

Securities are offered through Finalis Securities LLC Member FINRA/SIPC. S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities

# ALTERNATIVE PUBLIC OFFERINGS (APO) TEAM

## STRONG TRACK RECORD OF FACILITATING APO'S IN THE LIFE SCIENCES INDUSTRY

APO Webinar, "Reverse Mergers and SPACS:

Are Alternative Public Offerings the New Normal For Biotech's Going Public?" - March 18th, 2021 https://hubs.ly/H0JLhtK0



### **STEPHEN ALICANTI**

Partner DLA Piper, LLC (US)



## **SCOTT JANSSEN**

Managing Director

LS Associates

Part of the broader LifeSci Partner platform supporting over 200 clients with IR, PR, partnering / BD, and virtual CFO services



## MIKE MONTGOMERY

Managing Partner

Effectus Group

Public filings, audit preparation, mergers and acquisitions, business combinations, financial due diligence, and integration



## **SCOTT JORDAN**

Founder / CEO

S Jordan Associates

Raise private placements and concurrent financings, licensing / partnership agreements, M&A, and APOs – Reverse / SPAC




## **DAVID STRUPP**

Co-CEO Ignyte Acquisition Corp.

Investment banker facilitating 18 reverse merger transactions and concurrent financings and SPAC Sponsor - *Ignyte* 

## APO SERVICES - INCEPTION TO CLOSING TRANSACTIONS



# APO PUBLIC READINESS CHECKLIST

Strategic	Have you built an IPO or De-SPAC roadmap with specific subject matter experts, work stream, and milestones?
-	Who is the project owner / manager and do they have experience with this complex process?
	Has the board reviewed the plan and key dates?
	Have you performed a Board "audit" to make sure you have the people, skills, and governance in place to lead a company into and operate effectively as a public company?
	Are the internal shareholders and experts on the Board held accountable for their portion of the project?
	Have you engaged a team of expert consultants to support the project (e.g. attorney's, financial and technical accounting, consultants, auditors, D&O insurance providers)?
	Have you prepared accurate, reliable, and timely financial and scientific reports that will be required as a public company?
	Do you have reliable forecasting and subsequent actual to forecast reporting?
Finance / Accounting	Reviewed monthly closing book process / gap analysis necessary?
•	Team in place to implement financial planning and analysis including the review of budgt vs. actual processes?
	Audited financials? If not, has the company received quotations from potentail auditing firms?
	Company discussed with management / Board final selection of auditors?
	Company worked with auditors / director of finance from an accounting firm to complete the audit?
	Completed a 409A valuation that can be substantiated under PCAOB standards?
	Reviewed the cap table ensuring all supporting documentation in place including all financial transactions?
	Set up data base to collect company information such as contracts, stock option grants, financial statements for efficient audit process?
Capital Raise	Developed a plan and timeline for next financing?
Capital Kaise	Completed an investor deck review by Investor Relations and financial experts ensuring synergistic with financial forecasts and budget?
	Reviewed 5 / 10-year financial plan and balance sheet?
	Reviewed a list of possible Series / Cross-over investors and selected a banker to assist with the process?
	Initiated the IPO / De-SPAC roadmap with estimated timelines, assigned workstreams to stakeholders and consultants?

#### ALTERNATIVE PUBLIC OFFERINGS (APO)

### CASE STUDY

Securities are offered through Finalis Securities LLC Member FINRA/SIPC. S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.

## SALARIUS PHARMACEUTICALS REVERSE MERGES INTO FLEX PHARMA (JULY, 2019)

- Salarius Pharmaceutical (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced closing a merger with Flex Pharma, Inc.'s wholly owned subsidiary on July 19, 2019
- The newly combined company focused on the continued development of Salarius' clinical pipeline, which targets rare, orphan cancers with lead compound, Seclidemstast, a LSD1 inhibitor (epigenetics validated target)
- Healthios Capital Markets (now Third500 <u>https://www.third500.com/</u>) served as financial advisor in the transaction to Salarius Pharmaceuticals and Wedbush PacGrow advised Flex Pharma

Allocation Percentage - from Summary of Proposed Terms	\$M	%	
Flex Enterprise Value - "Shell"	\$7.2		
Flex Cash at Close	\$3.1		FLEXPharma
Flex Total Fair Value	\$10.3		
Salarius Total Fair Value	\$36.0		Salarius PHARMACEUTICALS The Cancer Epigenetics Company
Total Fair Value of Newco	\$46.3		\$46.3M Deal Value
Allocation Percentage			
Flex	2	22.3%	
Salarius	7	77.7%	

## TIMELINE / MILESTONES FROM INCEPTION TO REVERSE MERGER CLOSING

FLEXPharma	٦			10	Salarius PHARMACEUTICALS		2020
2018			20	19	NASDAQ: SLF	RX	2020
↓ ↓	Ļ	↓ ↓	<b>V</b>	↓ ↓	<b>V</b>	↓ ▼	
1Q - 2Q 3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q
<ul> <li>Established Connections with</li> <li>Signed CD/ / Complete</li> <li>Banks via</li> <li>Diligence</li> <li>Banks via</li> <li>Diligence</li> <li>Initiated</li> <li>Conferences</li> <li>Negotiatio</li> <li>Banker</li> <li>Exchange</li> <li>Introductions</li> <li>Throductions</li> <li>Awarded C</li> <li>Auctions</li> <li>Flex Shell</li> <li>Submitted</li> <li>Selected, &gt;</li> <li>Proposals to</li> <li>Reverse</li> <li>Reverse</li> <li>Reverse</li> <li>Financial</li> <li>Audit</li> <li>Complete</li> <li>Cast</li> <li>Cast&lt;</li></ul>	<ul> <li>Board</li> <li>Approval -</li> <li>Merger with</li> <li>Flex Pharma</li> <li>Closed</li> <li>\$6.4M Series</li> <li>A Financing</li> <li>Negotiated</li> <li>Merger</li> <li>Agreement /</li> </ul>	<ul> <li>Board Resolutions Approved Including Merger Agreement, Reverse Stock Split, Name Change</li> <li>Formation of Merger Sub</li> <li>Submitted SEC / NASDAQ Applications Including S-4 Filing - Financial Statements, Risk Factors, MD&amp;A</li> </ul>	<ul> <li>Responded to NASDAQ Comment Letter</li> <li>S-4 declared effective by SEC</li> <li>Obtained CUSIP</li> <li>S-3 Shelf Offering Remained Active</li> <li>Met NASDAQ Deadlines for Shareholder Equity / Minimum Price Per Share Bid Price (&gt;\$1.00)</li> </ul>	<ul> <li>Secured Stockholder Votes in Favor of Merger</li> <li>Prospectus Supplement / Comfort Letter</li> <li>Reverse Split: 25:1</li> <li>Closed / Announced Merger</li> <li>Listing on NASDAQ</li> <li>Sold Flex Subsidiary - HOTSHOT</li> <li>Filed 8-K/A</li> <li>Launched S3 Offering</li> </ul>	<ul> <li>Secured \$10.9M</li> <li>Equity line</li> <li>from Aspire</li> <li>Capital From</li> <li>Salarius' S-3</li> <li>Shelf</li> <li>Registration</li> <li>Drew Down</li> <li>\$2.6M in</li> <li>Aggregate</li> <li>Proceeds</li> <li>from Equity</li> <li>Line</li> <li>Ladenburg</li> <li>Selected for</li> <li>S1 Offering</li> <li>Held Annual</li> <li>Meeting of</li> <li>Stockholders</li> </ul>	<ul> <li>Filed S-1 Offering</li> <li>Raised \$11M From \$1 Prior to COVID Crisis Funding SLRX Through Read-Out of Clinical Milestones in 2021 (Ewing Sarcoma Phase 1 / 2 Study)</li> <li>Filed 4Q 10Q and 2019 10K</li> <li>Received Fast Track Designation</li> </ul>	<ul> <li>Filed 1Q 2020 10Q</li> <li>Launched Initiatives to Drive Trading Volume / Stock Price Purchases of Salarius Stock by Retail and Institutional Investors in Secondary Market – Hired IR / PR Firm</li> <li>Filed Proxy</li> <li>Announced Annual Meeting</li> </ul>

#### Appendix – SPAC vs. IPO

Securities are offered through Finalis Securities LLC Member FINRA/SIPC. S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities

# Initial Public Offering (IPO) vs Special Purpose Acquisition Company SPAC

Pro and Con Con	Pro	
	IPO	SPAC
Certainty of Pricing, Pre-Transaction Launch and Closing	Lower: "2" Step Process - From Closing of the Crossover to the Pricing of the Offering, Significant Risk Associated with Intrinsic (Pipeline News) and Extrinsic (Macro Issues) Events Creating Risk Around the Raise and Valuation	Higher: "1" Step Process - Ability for Crossover and De-SPAC to Close Simultaneously; Increased Certainty of Pricing / Closing Provided Deal Negotiated Behind "Closed Doors" Between SPAC Sponsor and Targeted Company
Timeline / Considerations for Going Public	Longer (~12+ Months): Extended Timeline of a Typical IPO Process Given Crossover and IPO Not Closed Simultaneously and Road Show Requirement for Pricing of the deal	<b>Shorter (3-6 Months):</b> For a Merger Target, the Timeline for Going Public is shorter than a traditional IPO given "1" step process (De-SPAC / Crossover)
Potential Liquidity Event for Existing Shareholders	Νο	Yes
Potential Liquidity Event for Existing Shareholders Potential Management Earn-Outs and Structuring Flexibility	No	Yes Yes: Merger Target Could Earn Future Equity Milestones if Pipeline Delivers More than the SPAC Sponsor Expected, or if Certain Price Targets Are Met
Potential Management Earn-Outs		<b>Yes:</b> Merger Target Could Earn Future Equity Milestones if Pipeline Delivers More than the SPAC

# Initial Public Offering (IPO) vs Special Purpose Acquisition Company SPAC

	IPO	SPAC
Valuation	<b>Pro:</b> Priced Via a Multi-Day Book-Building Process with Multiple Investors Putting in their Orders; <b>Con's:</b> IPO Pricing Largely Driven by the Pricing Appetite of a Few Large Accounts; Risk of Underpriced Public Offerings Resulting in Stock Price Increasing by 20- 40% Post-Close Representing Significant "Value Left on the Table	<b>Pro's:</b> Higher Valuation - SPAC Price Discovery is Largely a Direct Negotiation Between the SPAC Sponsor and the Target; Concurrent PIPE Acts as an Important Source of Price Validation Supporting the Valuation Negotiated by the Sponsor; <b>Con's:</b> Higher Valuations Negotiated to Offset Increased Dilution Associated with Sponsor Shares / Warrants; Limiting Number of Companies Eligible to Participate (Higher Enterprise Value Required to Transact)
Dilution	<b>Pro:</b> No Dilution From Sponsor Shares / Warrants; <b>Con:</b> Sell 25-33% in the Crossover Round + Sell Another 20-30% in the IPO + Greenshoe Dilution	Pro: Because SPACs Replace the Two-Step of Crossover and IPO, Valuations Can Approach that of the IPO Itself Resulting in Less Total Dilution (10-15%) Adding Value to Existing Shareholders; <b>Con:</b> Additional Dilution Associated with Sponsor Shares, Private Warrants and Public Warrants
Transaction Structure	<b>Rigid</b> Equity Financing Structure with Investors Receiving Preferred Stock, Liquidation Preferences, and Other Protections at Founder's Expense	Flexible Deal Structure With Earnouts Allows Both for Management to Receive Additional Compensation Upon Company Performance
Crossover / Buy Side Allocations	Lower: Especially in "Hot" IPOs (Oversubscribed), Crossover / Buy Side Investors Oftentimes Receive Smaller Allocations	<b>Higher:</b> Significant Allocation of Capital to Invest Over Time Especially Meaningful to Large Investment Funds
Optimal Profile: Pre-Crossover Private Company		<ul> <li>(1) Pipeline / Meaningful Clinical News Flow over Next</li> <li>1-3 Years (2) Raised \$25 - \$100M in Preferred Stock</li> <li>Financings (3) Access to Crossover Investors</li> </ul>

# Initial Public Offering (IPO) vs Special Purpose Acquisition Company SPAC

	IPO	SPAC
Financial Disclosures – SPAC Allowable Disclosures Under PSLRA Review and Subject to Change	Historical Financial Statements Required Stemming From The Private Securities Litigation Reform Act (PSLRA); No Safe Harbor for Forward-Looking Statements	<b>Pro:</b> Safe Harbor for Forward-Looking Statements Applies Providing Companies with More Flexibility to Share Future Earnings Projections Making a Deal More Attractive Especially with Pre-Revenue Companies; <b>Con</b> : There's an Emerging Class of Plaintiff Attorney's Looking at the space as a Result
Reduced Investor Risk	N/A	Reduced Investor Risk Given Shares are Redeemable and Oftentimes Receive a Free Warrant Which They Can Keep Even if Not Participating in the De-SPAC
Merger Target	N/A	With a Specific Valuation Mutually Agreed for the Merger, There's a Clear Timetable for Closing the Deal and Trading as a Public Company (the "de- SPAC" process); For a Merger Target, Both the Timeline to Being Public, as well as the Pre-Specified Scale of the Valuation and Capital Raise are Better "Controlled" in a SPAC Process
Post-Finance Outlook	Oftentimes Need to Conduct Several Financing Processes Within 8-12 Months Distracting Management from Company Operations	Public Company with Strong Institutional Investor Base and Access to Public Capital Markets Facilitating Management Focus on Operations
Liquidity	Existing Shareholders Generally Required to Wait Six Months From Closing of the IPO Prior to Selling Shares	Existing Shareholders (Sponsor) Generally Required to Wait One Year From Closing of the Business Combination (De-SPAC) Prior to Selling Shares



### S. JORDAN ASSOCIATES

Life Sciences Consultant & Registered Representative

SCOTT JORDAN Founder / CEO

512 N. McClurg #4604 Chicago, IL 60611

312-451-6210 scott@sjordanassociates.com www.sjordanassociates.com



**()** @

@sjordanassociat

